R. Ahrens, I. Peter, K. Lip, G. Bode, and C. , Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation, Discov. Med, vol.13, pp.445-450, 2012.

E. Anderberg, T. Lindmark, and P. Artursson, Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route, Pharmaceutical Research, vol.10, issue.6, pp.857-864, 1993.
DOI : 10.1023/A:1018909210879

J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther et al., Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008.

E. Arbit, M. Goldberg, I. Gomez-orellana, and S. Majuru, Oral heparin: status review, Thromb. J, vol.4, pp.1-7, 2006.

. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors, Cardiovasc. Drug. Rev, vol.20, pp.37-52, 2002.

K. Bauer, Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa, Journal of Thrombosis and Haemostasis, vol.315, pp.12-19, 2011.
DOI : 10.1111/j.1538-7836.2011.04321.x

R. Baughman, S. Kapoor, and R. Agarwal, Oral Delivery of Anticoagulant Doses of Heparin : A Randomized, Double-Blind, Controlled Study in Humans, Circulation, vol.98, issue.16, pp.1610-1615, 1998.
DOI : 10.1161/01.CIR.98.16.1610

A. Clausen, C. Kast, and A. Bernkop-schnürch, The role of glutathione in the permeation enhancing effect of thiolated polymers, Pharmaceutical Research, vol.19, issue.5, pp.602-608, 2002.
DOI : 10.1023/A:1015345827091

A. Cohen, V. Tapson, J. Bergmann, J. Goldhaber, S. Kakkar et al., Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study, The Lancet, vol.371, issue.9610, pp.387-394, 2008.
DOI : 10.1016/S0140-6736(08)60202-0

F. Donat, J. Duret, A. Santoni, R. Cariou, J. Necciari et al., The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers, Clinical Pharmacokinetics, vol.359, issue.Supplement 2, pp.1-9, 2002.
DOI : 10.2165/00003088-200241002-00001

E. Dray, B. Mulloy, and T. Barrowcliffe, Heparin and low-molecular-weight heparin, Thromb. Haemost, vol.99, pp.897-818, 2008.

J. Eikelboom, S. Zelenkofske, and C. Rusconi, Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.382-387, 2010.
DOI : 10.1161/ATVBAHA.110.203117

T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-matsumoto, N. Sugiyama et al., DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles, J. Thromb. Haemost, vol.6, pp.1542-1549, 2008.

V. Fuster, L. Rydén, D. Cannom, H. Crijns, A. Curtis et al., 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA, pp.269-367, 2006.
DOI : 10.1161/CIR.0b013e318214876d

M. Goldberg and I. Gomez-orellana, Challenges for the oral delivery of macromolecules, Nature Reviews Drug Discovery, vol.2, issue.4
DOI : 10.1038/nrd1067

V. Grabovac, T. Schmitz, F. Föger, and A. Berknop-schnürch, Papain: An Effective Permeation Enhancer for Orally Administered Low Molecular Weight Heparin, Pharmaceutical Research, vol.20, issue.6, pp.1001-1006, 2007.
DOI : 10.1007/s11095-006-9226-8

P. Gross and J. Weitz, New Anticoagulants for Treatment of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.3
DOI : 10.1161/ATVBAHA.108.162677

N. Haginoya, S. Kobayashi, S. Komoriya, T. Yoshino, T. Nagata et al., Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units, Bioorganic & Medicinal Chemistry, vol.12, issue.21, pp.5579-5586, 2004.
DOI : 10.1016/j.bmc.2004.08.001

N. Hauel, H. Nar, H. Priepke, U. Ries, J. Stassen et al., Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors, Journal of Medicinal Chemistry, vol.45, issue.9, pp.1757-66, 2002.
DOI : 10.1021/jm0109513

P. Hayes, B. Ross, B. Thomas, and I. Toth, Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin, Bioorganic & Medicinal Chemistry, vol.14, issue.1, pp.143-152, 2006.
DOI : 10.1016/j.bmc.2005.08.004

R. Hejazi and M. Amiji, Chitosan-based gastrointestinal delivery systems, Journal of Controlled Release, vol.89, issue.2, pp.151-165, 2003.
DOI : 10.1016/S0168-3659(03)00126-3

J. Herbert, M. Petitou, J. Lormeau, R. Cariou, J. Necciari et al., SR 90107A/Org 31540, a Novel Anti-Factor Xa Antithrombotic Agent, Cardiovascular Drug Reviews, vol.3, issue.1, pp.1-26, 1997.
DOI : 10.1016/0049-3848(94)90232-1

J. Hirsh, Current anticoagulant therapy???unmet clinical needs, Thrombosis Research, vol.109, issue.109, 2003.
DOI : 10.1016/S0049-3848(03)00250-0

J. Hirsh and R. Raschke, Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004.
DOI : 10.1378/chest.126.3_suppl.188S

V. Hoffart, N. Ubrich, A. Lamprecht, C. Bachelier, C. Vigneron et al., Microencapsulation of Low Molecular Weight Heparin into Polymeric Particles Designed with Biodegradable and Nonbiodegradable Polycationic Polymers, Drug Delivery, vol.10, issue.1, pp.1-7, 2003.
DOI : 10.1080/713840325

V. Hoffart, A. Lamprecht, P. Maincent, T. Lecompte, C. Vigneron et al., Oral bioavailability of a low molecular weight heparin using a polymeric delivery system, Journal of Controlled Release, vol.113, issue.1, pp.38-42, 2006.
DOI : 10.1016/j.jconrel.2006.03.020

R. Hull, A. Kakkar, V. Marder, R. Baughman, A. Leone-bay et al., Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement, Journal of Thrombosis and Haemostasis, vol.1, p.148, 2001.
DOI : 10.1111/j.1538-7836.2003.tb05438.x

Y. Ito, T. Kusawake, R. Prasad, Y. Sugioka, N. Shibata et al., Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies, International Journal of Pharmaceutics, vol.317, issue.2, pp.114-119, 2006.
DOI : 10.1016/j.ijpharm.2006.02.056

L. Jaques, Heparin, Pharmacol. Rev, vol.31, pp.100-166, 1980.
DOI : 10.1021/ba-1980-0187.ch023

Y. Jiao, N. Ubrich, M. Marchand-arvier, C. Vigneron, M. Hoffman et al., In Vitro and In Vivo Evaluation of Oral Heparin-Loaded Polymeric Nanoparticles in Rabbits, Circulation, vol.105, issue.2, pp.230-235, 2002.
DOI : 10.1161/hc0202.101988

L. Jin, J. Abrahams, R. Skinner, M. Petitou, R. Pike et al., The anticoagulant activation of antithrombin by heparin, Proc. Natl. Acad. Sci. USA, pp.14683-14688, 1997.
DOI : 10.1073/pnas.94.26.14683

S. Kaatz, P. Korrides, D. Garcia, A. Spyrolous, M. Crowther et al., Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, American Journal of Hematology, vol.171, issue.Suppl 1, pp.141-146, 2012.
DOI : 10.1002/ajh.23202

C. Kast, D. Guggi, N. Langoth, and A. Bernkop-schnürch, Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil

H. Kawaji, M. Ishii, Y. Tamaki, K. Sasaki, and M. Takagi, Edoxaban for prevention of venous thromboembolism after major orthopedic surgery, Orthopedic Research and Reviews, vol.4, pp.53-64, 2012.
DOI : 10.2147/ORR.S24583

S. Kim, E. Lee, B. Vaishali, S. Lee, Y. Lee et al., Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates, Journal of Controlled Release, vol.105, issue.1-2, pp.32-42, 2005.
DOI : 10.1016/j.jconrel.2005.03.018

K. Ogata, J. Mendell-harary, M. Tachiban, H. Masumoto, T. Oguma et al., Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.43, issue.suppl A, pp.743-753, 2010.
DOI : 10.1177/0091270009351883

R. Paliwal, S. Paliwal, G. Agrawal, and S. Vyas, Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012.
DOI : 10.1002/med.20217

R. Paliwal, S. Paliwal, G. Agrawal, and S. Vyas, Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation, International Journal of Pharmaceutics, vol.422, issue.1-2, pp.179-184, 2012.
DOI : 10.1016/j.ijpharm.2011.10.048

S. Peltier, J. Oger, F. Lagarce, W. Couet, and J. Benoit, Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006.
DOI : 10.1007/s11095-006-0022-2

E. Perzborn, A. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig et al., In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor, Journal of Thrombosis and Haemostasis, vol.10, issue.3, pp.514-521, 2005.
DOI : 10.1016/0049-3848(89)90210-7

E. Perzborn, Factor Xa inhibitors. New anticoagulants for secondary haemostasis, Hämostaseologie, vol.29, pp.260-267, 2009.

E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, and F. Misselwitz, The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor, Nature Reviews Drug Discovery, vol.110, issue.1, pp.61-75, 2011.
DOI : 10.1038/nrd3185

M. Petitou and J. Herbert, H??parines de synth??se., m??decine/sciences, vol.15, issue.11, pp.1325-1328, 1999.
DOI : 10.4267/10608/1270

M. Petitou, B. Casu, and U. Lindahl, 1976???1983, a critical period in the history of heparin: the discoveryof the antithrombin binding site, Biochimie, vol.85, issue.1-2, pp.83-89, 2003.
DOI : 10.1016/S0300-9084(03)00078-6

J. Weitz and S. Bates, New anticoagulants, Journal of Thrombosis and Haemostasis, vol.119, issue.8, pp.1843-1853, 2005.
DOI : 10.1111/j.1538-7836.2004.00890.x

URL : https://hal.archives-ouvertes.fr/hal-00935589

D. Weitz and J. Weitz, Update on heparin: what do we need to know?, Journal of Thrombosis and Thrombolysis, vol.86, issue.2, pp.199-207, 2010.
DOI : 10.1007/s11239-009-0411-6

J. Weitz, J. Eikelboom, and M. Samama, New Antithrombotic Drugs, Chest, vol.141, issue.2, pp.120-151, 2012.
DOI : 10.1378/chest.11-2294

W. Wienen, J. Stassen, and H. Priepke, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, Thrombosis and Haemostasis, vol.98, pp.155-162, 2007.
DOI : 10.1160/TH07-03-0183

P. Wong, D. Pinto, and D. Zhang, Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor, Journal of Thrombosis and Thrombolysis, vol.38, issue.1, pp.478-492, 2011.
DOI : 10.1007/s11239-011-0551-3

Y. Yun, Y. Cho, K. Park, M. Zafar, D. Vorchheimer et al., Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber, Ad. Drug Del. Rev, 2012.

K. Bauer, D. Hawkins, P. Peters, M. Petitou, J. Herbert et al., Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2002.
DOI : 10.1111/j.1527-3466.2002.tb00081.x

J. Hirsh and R. Raschke, Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004.
DOI : 10.1378/chest.126.3_suppl.188S

M. Samama and G. Gerotziafas, Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2003.
DOI : 10.1016/S0049-3848(03)00030-6

L. Reddy, C. Dubernet, L. Mouelhi, S. Marque, P. Desmaële et al., A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, Journal of Controlled Release, vol.124, issue.1-2, pp.20-27, 2007.
DOI : 10.1016/j.jconrel.2007.08.018

G. S. Kelly, Squalene and its potential clinical uses, Alt. Med. Rev, vol.4, pp.29-36, 1999.

H. Kolb and K. Sharpless, The growing impact of click chemistry on drug discovery, Drug Discovery Today, vol.8, issue.24, pp.1128-1137, 2003.
DOI : 10.1016/S1359-6446(03)02933-7

D. Hoarau, M. Boustta, C. Braud, and M. Vert, New amphiphilic derivatives of heparin, grafted to bile acids, useful as vectors for oral delivery, 2003.

E. Van-tamelen and T. Curphey, The selective oxidation of the terminal double bonds in squalene, Tetrahedron Letters, vol.3, issue.3, pp.121-124, 1962.
DOI : 10.1016/S0040-4039(00)71112-9

A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Berknop-schnürch, Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010.

T. Leonard, D. Coughlan, and A. Cullen, Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011.

J. Meissonnier, N. Sicre, G. Sabate, G. Dubreucq, V. Nancy-portebois et al., Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011.

A. Ramadan, F. Lagarce, A. Tessier-marteau, O. Thomas, P. Legras et al., Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Nanomed, vol.6, pp.2941-2951, 2011.

N. Aher, S. Pore, and S. Patil, Design, synthesis, and micellar properties of bile acid dimers and oligomers linked with a 1,2,3-triazole ring, Tetrahedron, vol.63, issue.52, pp.12927-12934, 2007.
DOI : 10.1016/j.tet.2007.10.042

B. Spraul, S. Suresh, J. J. Smith, and D. , Synthesis and Electronic Factors in Thermal Cyclodimerization of Functionalized Aromatic Trifluorovinyl Ethers, Journal of the American Chemical Society, vol.128, issue.21, pp.7055-7064, 2006.
DOI : 10.1021/ja0600227

H. Lin and C. Walsh, A Chemoenzymatic Approach to Glycopeptide Antibiotics, Journal of the American Chemical Society, vol.126, issue.43, pp.13998-14003, 2004.
DOI : 10.1021/ja045147v

L. Jin, J. Abrahams, R. Skinner, M. Petitou, R. Pike et al., The anticoagulant activation of antithrombin by heparin, Proc. Natl. Acad. Sci. USA, pp.14683-14688, 1997.
DOI : 10.1073/pnas.94.26.14683

Y. Lee, J. Nam, H. Shin, and Y. Byun, Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3120, 2001.
DOI : 10.1161/hc5001.100627

Y. Lee, S. Kim, and Y. Byun, Oral delivery of new heparin derivatives in rats, Pharmaceutical Research, vol.17, issue.10, pp.1259-1264, 2000.
DOI : 10.1023/A:1026474919869

J. Harenberg, Development of idraparinux and idrabioparinux for anticoagulant therapy

P. Zandberg, R. G. Van-amsterdam, C. A. Van-boeckel, and D. G. Meuleman, SR 90107/org 31540, a novel anti-Factor Xa antithrombotic agent, Cardiov. Drug Rev, vol.15, pp.1-26, 1997.

A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Bernkop-schnürch, Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010.

N. A. Motlekar and B. B. Youan, The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins, Journal of Controlled Release, vol.113, issue.2, pp.91-101, 2006.
DOI : 10.1016/j.jconrel.2006.04.008

K. A. Bauer, D. W. Hawkins, P. C. Peters, M. Petitou, J. M. Herbert et al., Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2002.
DOI : 10.1111/j.1527-3466.2002.tb00081.x

J. Meissonnier, N. Sicre, G. Sabate, G. Dubreucq, V. Nancy-portebois et al., Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011.

T. W. Leonard, D. C. Coughlan, and A. Cullen, Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011.

A. Ramadan, F. Lagarce, A. Tessier-marteau, O. Thomas, P. Legras et al., Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Pharm, vol.422, pp.179-184, 2012.

D. Desmaële, R. Gref, and P. Couvreur, Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012.
DOI : 10.1016/j.jconrel.2011.07.038

G. S. Kelly, Squalene and its potential clinical uses, Alter. Med Rev, vol.4, pp.29-36, 1999.

S. Mouelhi, F. Rocco, N. Dereuddre-bosquet, and P. Clayette, Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006.

R. Paliwal, S. R. Paliwal, G. P. Agrawal, and S. P. Vyas, Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012.
DOI : 10.1002/med.20217

P. Y. Hayes, B. P. Ross, B. G. Thomas, and I. Toth, Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin, Bioorganic & Medicinal Chemistry, vol.14, issue.1
DOI : 10.1016/j.bmc.2005.08.004

W. Sun, S. Mao, and D. Mei, Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin, European Journal of Pharmaceutics and Biopharmaceutics, vol.69, issue.2, pp.417-425, 2008.
DOI : 10.1016/j.ejpb.2008.01.016

W. Sun, S. Mao, Y. Wang, V. B. Junyaprasert, T. Zhang et al., Bioadhesion and oral absorption of enoxaparin nanocomplexes, International Journal of Pharmaceutics, vol.386, issue.1-2, pp.275-281, 2010.
DOI : 10.1016/j.ijpharm.2009.11.025

D. Y. Lee, J. Lee, S. Lee, S. K. Kim, and Y. Byun, Liphophilic complexation of heparin based on bile acid for oral delivery, Journal of Controlled Release, vol.123, issue.1, pp.39-45, 2007.
DOI : 10.1016/j.jconrel.2007.07.013

H. T. Moon, Y. K. Lee, J. K. Han, and Y. Byun, A novel formulation for controlled release of heparin???DOCA conjugate dispersed as nanoparticles in polyurethane film, Biomaterials, vol.22, issue.3, pp.281-289, 2001.
DOI : 10.1016/S0142-9612(00)00194-0

S. Sen and G. Prestwich, Trisnorsqualene alcohol, a potent inhibitor of vertebrate squalene epoxidase, Journal of the American Chemical Society, vol.111, issue.4, pp.1508-1510, 1989.
DOI : 10.1021/ja00186a062

P. Legrand, S. Lesieur, A. Bochot, R. Gref, W. Raatjes et al., Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation, International Journal of Pharmaceutics, vol.344, issue.1-2, pp.33-43, 2007.
DOI : 10.1016/j.ijpharm.2007.05.054

URL : https://hal.archives-ouvertes.fr/hal-00180715

. Venous, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.133, pp.844-86, 2008.

P. Gross and J. Weitz, New Anticoagulants for Treatment of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.3
DOI : 10.1161/ATVBAHA.108.162677

J. Eikelboom, S. Zelenkofske, and C. Rusconi, Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.382-387, 2010.
DOI : 10.1161/ATVBAHA.110.203117

A. Hrs-focused-updates-incorporated, A. Into-the, and . Esc, Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, vol.123, pp.269-367, 2006.

L. , D. Wang, T. Leip, E. Larson, M. Levy et al., Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study, Circulation, vol.110, pp.1042-1046, 2004.

J. Hirsh and R. Raschke, Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004.
DOI : 10.1378/chest.126.3_suppl.188S

J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther et al., Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence- Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008.

K. Bauer, D. W. Hawkins, D. Peters, P. Petitou, M. Herbert et al., Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents - The Selective Factor Xa Inhibitors, Cardiovascular Drug Reviews, vol.32, issue.Suppl 1, pp.37-52, 2006.
DOI : 10.1111/j.1527-3466.2002.tb00081.x

J. Weitz and S. Bates, New anticoagulants, Journal of Thrombosis and Haemostasis, vol.119, issue.8, pp.1843-1853, 2005.
DOI : 10.1111/j.1538-7836.2004.00890.x

URL : https://hal.archives-ouvertes.fr/hal-00935589

J. Herbert, M. Petitou, J. Lormeau, R. Cariou, J. Necciari et al., SR 90107A/Org 31540, a Novel Anti-Factor Xa Antithrombotic Agent, Cardiovascular Drug Reviews, vol.3, issue.1, pp.1-26, 1997.
DOI : 10.1016/0049-3848(94)90232-1

M. Samama and G. Gerotziafas, Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2011.
DOI : 10.1016/S0049-3848(03)00030-6

L. Jaques, Heparin, Pharmacol Rev, vol.31, pp.100-66, 1980.
DOI : 10.1021/ba-1980-0187.ch023

C. Becattini, M. Vedovati, and G. Agnelli, Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature, Thrombosis Research, vol.129, issue.3, pp.392-400, 2012.
DOI : 10.1016/j.thromres.2011.12.014

K. Bauer, Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa, Journal of Thrombosis and Haemostasis, vol.315, issue.9, pp.12-19, 2011.
DOI : 10.1111/j.1538-7836.2011.04321.x

Y. Lee, J. Nam, H. Shim, and Y. Byun, Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3136, 2001.
DOI : 10.1161/hc5001.100627

S. Kim, D. Lee, E. Lee, Y. Lee, C. Kim et al., Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant, Journal of Controlled Release, vol.120, issue.1-2, pp.4-10, 2007.
DOI : 10.1016/j.jconrel.2007.03.008

V. Grabovac, T. Schmitz, F. Föger, and A. Bernkop-schnürch, Papain: An Effective Permeation Enhancer for Orally Administered Low Molecular Weight Heparin, Pharmaceutical Research, vol.20, issue.6, pp.1001-1006, 2007.
DOI : 10.1007/s11095-006-9226-8

C. Kast, D. Guggi, N. Langoth, and A. Bernkop-schnürch, Development and in vivo evaluation of an oral delivery system for low molecular

T. Rivera, A. Leone-bay, D. Paton, H. Leipold, and R. Baughman, Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations, Pharmaceutical Research, vol.14, issue.12, pp.1830-1834, 1997.
DOI : 10.1023/A:1012160703533

R. Baughman, S. Kappor, R. Agarwal, J. Kisicki, F. Catella-lawson et al., Oral Delivery of Anticoagulant Doses of Heparin : A Randomized, Double-Blind, Controlled Study in Humans, Circulation, vol.98, issue.16, pp.1610-1615, 1998.
DOI : 10.1161/01.CIR.98.16.1610

A. Leone-bay, D. Paton, B. Variano, H. Leipold, T. Rivera et al., Acylated non-??-amino acids as novel agents for the oral delivery of heparin sodium, USP, Journal of Controlled Release, vol.50, issue.1-3, pp.41-49, 1998.
DOI : 10.1016/S0168-3659(97)00101-6

W. Sun, S. Mao, D. Mei, and T. Kissel, Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin, European Journal of Pharmaceutics and Biopharmaceutics, vol.69, issue.2, pp.417-425, 2008.
DOI : 10.1016/j.ejpb.2008.01.016

M. Chen, H. Wong, K. Lin, H. Chen, S. Wey et al., The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin, Biomaterials, vol.30, issue.34, pp.6629-6637, 2009.
DOI : 10.1016/j.biomaterials.2009.08.030

W. Sun, S. Mao, Y. Wang, V. Junyaprasert, T. Zhang et al., Bioadhesion and oral absorption of enoxaparin nanocomplexes, International Journal of Pharmaceutics, vol.386, issue.1-2, pp.275-281, 2010.
DOI : 10.1016/j.ijpharm.2009.11.025

R. Paliwal, S. Paliwal, G. Agrawal, and S. Vyas, Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation, International Journal of Pharmaceutics, vol.422, issue.1-2, pp.179-184, 2012.
DOI : 10.1016/j.ijpharm.2011.10.048

V. Hoffart, N. Ubrich, A. Lamprecht, K. Bachelier, C. Vigneron et al., Microencapsulation of Low Molecular Weight Heparin into Polymeric Particles Designed with Biodegradable and Nonbiodegradable Polycationic Polymers, Drug Delivery, vol.10, issue.1, pp.1-7, 2003.
DOI : 10.1080/713840325

V. Hoffart, A. Lamprecht, P. Maincent, T. Lecompte, C. Vigneron et al., Oral bioavailability of a low molecular weight heparin using a polymeric delivery system, Journal of Controlled Release, vol.113, issue.1, pp.38-42, 2006.
DOI : 10.1016/j.jconrel.2006.03.020

S. Kim, E. Lee, B. Vaishali, S. Lee, Y. Lee et al., Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates, Journal of Controlled Release, vol.105, issue.1-2, pp.32-42, 2005.
DOI : 10.1016/j.jconrel.2005.03.018

A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Bernkop-schnürch, Development and in vivo bioavailability study of an oral fondaparinux delivery system, European Journal of Pharmaceutical Sciences, vol.41, issue.3-4, pp.489-497, 2010.
DOI : 10.1016/j.ejps.2010.08.001

A. Ramadan, F. Lagarce, A. Tessier-marteau, O. Thomas, P. Legras et al., Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int J Pharm, vol.422, pp.179-184, 2012.

T. Leonard, D. Coughlan, and A. Cullen, Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011.

J. Meissonnier, N. Sicre, G. Sabate, G. Dubreucq, V. Nancy-portebois et al., Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011.

G. Kelly, Squalene and its potential clinical uses, Altern Med Rev, vol.4, pp.29-36, 1999.

D. Desmaële, R. Gref, and P. Couvreur, Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2011.
DOI : 10.1016/j.jconrel.2011.07.038

P. Couvreur, S. B. Reddy, L. Hilaireau, H. Dubernet, C. Desmaële et al., Squalenoyl Nanomedicines as Potential Therapeutics, Squalenoyl nanomedicines as potential therapeutics, pp.2544-2548, 2006.
DOI : 10.1021/nl061942q

L. Reddy, H. Ferreira, C. Dubernet, S. Lepêtre-mouelhi, D. Desmaële et al., Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine, Journal of Nanoparticle Research, vol.18, issue.5, pp.887-891, 2008.
DOI : 10.1007/s11051-007-9322-7

L. Bildstein, H. Hillaireau, D. Desmaële, S. Lepêtre-mouelhi, C. Dubernet et al., Freeze-drying of squalenoylated nucleoside analogue nanoparticles, International Journal of Pharmaceutics, vol.381, issue.2, pp.140-145, 2009.
DOI : 10.1016/j.ijpharm.2009.04.002

J. Weitz, Emerging anticoagulants for the treatment of venous thromboembolism, Thrombosis and Haemostasis, vol.96, pp.274-84, 2006.
DOI : 10.1160/TH06-05-0234

R. Paliwal, S. Paliwal, G. Agrawal, and S. Vyas, Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012.
DOI : 10.1002/med.20217

W. Abdelwahed, G. Degobert, S. Stainmesse, and H. Fessi, Freeze-drying of nanoparticles: Formulation, process and storage considerations???, Advanced Drug Delivery Reviews, vol.58, issue.15, pp.1688-713, 2006.
DOI : 10.1016/j.addr.2006.09.017

A. Akhgari, A. Garekani, H. Sadeghi, F. Azimaie, and M. , Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery, International Journal of Pharmaceutics, vol.305, issue.1-2, pp.22-30, 2005.
DOI : 10.1016/j.ijpharm.2005.08.025

. Meuleman and . Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors, Cardiov. Drug. Rev, vol.20, pp.37-52, 2002.

. Venous, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.133, pp.844-86, 2008.

M. M. Samama and G. T. Gerotziafas, Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Research, vol.109, issue.1, pp.1-11, 2003.
DOI : 10.1016/S0049-3848(03)00030-6

J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther et al., Pharmacology and management of the vitamin K antagonists American College of Chest Physicians Evidence- Based Clinical Practice Guidelines, Chest, vol.8, issue.133, pp.160-198, 2008.

C. Becattini, M. C. Vedovati, and G. Agnelli, Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature, Thrombosis Research, vol.129, issue.3, pp.392-400, 2012.
DOI : 10.1016/j.thromres.2011.12.014

E. Nutescu, I. Chuatrisorn, and E. Hellenbart, Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, Journal of Thrombosis and Thrombolysis, vol.29, issue.2, pp.326-343, 2011.
DOI : 10.1007/s11239-011-0561-1

W. Miesbach, W. , and E. Seifried, New direct oral anticoagulants ??? current therapeutic options and treatment recommendations for bleeding complications, Thrombosis and Haemostasis, vol.108, issue.4, pp.1-7, 2012.
DOI : 10.1160/TH12-05-0319

R. Paliwal, S. R. Paliwal, G. P. Agrawal, and S. P. Vyas, Recent advances in search of oral heparin therapeutics, Medicinal Research Reviews, vol.21, issue.2, pp.388-409, 2012.
DOI : 10.1002/med.20217

A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Berknop-schnürch, Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, vol.41, pp.489-497, 2010.

A. Ramadan, F. Lagarce, A. Tessier-marteau, O. Thomas, P. Legras et al., Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int. J. Nanomed, vol.6, pp.2941-2951, 2011.

R. Couvreur and . Gref, Novel self assembling nanoparticles for the oral administration of fondaparinux : synthesis, characterization and in vivo evaluation

G. S. Kelly, Squalene and its potential clinical uses, Alt. Med. Rev, vol.4, pp.29-36, 1999.

B. Ralay-ranaivo, D. Borgel, E. Bianchini, P. Couvreur, and R. Gref, Development and in vivo evaluation of novel squalenoyl-fondaparinux nanoparticles as efficient delivery for oral administration of anticoagulant agents

B. Moazed and L. M. Hiebert, An in Vitro Study with an Ussing Chamber Showing That Unfractionated Heparin Crosses Rat Gastric Mucosa, Journal of Pharmacology and Experimental Therapeutics, vol.322, issue.1, pp.299-305, 2007.
DOI : 10.1124/jpet.106.116939

B. Moazed and L. M. Hiebert, Low Molecular Weight Heparins Cross Rat Gastric Mucosa Mounted in an Ussing Chamber, International Journal of Pharmacology, vol.4, issue.6, pp.431-442, 2008.
DOI : 10.3923/ijp.2008.431.442

B. Moazed and L. M. Hiebert, Movement of Heparins Across Rat Gastric Mucosa is Dependent on Molecular Weight and pH, Pharmaceutical Research, vol.234, issue.6, pp.189-195, 2009.
DOI : 10.1007/s11095-008-9751-8

E. Watanabe, M. Takahashi, and A. Hayashi, A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method, European Journal of Pharmaceutics and Biopharmaceutics, vol.58, issue.3, pp.659-665, 2004.
DOI : 10.1016/j.ejpb.2004.03.029

M. G. Lionato, M. E. Giordano, F. De-nuccio, G. Nicolardi, E. K. Hoffmann et al., Hypotonicity induced K+ and anion conductive pathways activation in eel intestinal epithelium, Journal of Experimental Biology, vol.208, issue.4, pp.749-760, 2005.
DOI : 10.1242/jeb.01440

N. Pantzar, S. Lundin, L. Wester, and B. R. Weström, Bidirectional Small-Intestinal Permeability in the Rat to Some Common Marker Molecules in vitro, Scandinavian Journal of Gastroenterology, vol.242, issue.8, pp.703-709, 1994.
DOI : 10.3109/00365529409092497

S. K. Kim, D. Y. Lee, E. Lee, Y. K. Lee, C. Y. Kim et al., Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant, Journal of Controlled Release, vol.120, issue.1-2, pp.4-10, 2007.
DOI : 10.1016/j.jconrel.2007.03.008

P. Artursson, K. Palm, and K. Luthman, Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv. Drug Del. Rev. In press, 2012.

. Irache, Combined hydroxypropyl-?-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur, J. Pharm. Sc, vol.38, pp.405-413, 2009.

A. L. Daugherty and R. J. Mrsny, Transcellular uptake mechanisms of the intestinal epithelial barrier Part one, Pharmaceutical Science & Technology Today, vol.2, issue.4, pp.144-151, 1999.
DOI : 10.1016/S1461-5347(99)00142-X

P. Mardones, D. Andrinolo, A. Csendes, and N. Lagos, Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique, Toxicon, vol.44, issue.5, pp.521-528, 2004.
DOI : 10.1016/j.toxicon.2004.07.003

M. V. Varma and R. Panchagnula, Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo, European Journal of Pharmaceutical Sciences, vol.25, issue.4-5, pp.445-453, 2005.
DOI : 10.1016/j.ejps.2005.04.003

C. M. Kruijtzer, J. H. Beijnen, and J. H. Schellens, Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview, The Oncologist, vol.7, issue.6, pp.516-530, 2002.
DOI : 10.1634/theoncologist.7-6-516

T. Partie, W. Discussion-generale-références-abdelwahed, G. Degobert, S. Stainmesse, and H. Fessi, Freeze-drying of nanoparticles: formulation, process and storage considerations, Adv. Drug Deliv. Rev, vol.58, pp.1688-713, 2006.

S. Lepêtre-mouelhi, D. Desmaële, N. J. Chafi, N. Couvreur, and P. , Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues, Adv. Funct. Mater, vol.18, pp.3715-3725, 2008.

L. Bildstein, H. Hillaireau, D. Desmaële, S. Lepêtre-mouelhi, C. Dubernet et al., Freeze-drying of squalenoylated nucleoside analogue nanoparticles, International Journal of Pharmaceutics, vol.381, issue.2, pp.140-145, 2009.
DOI : 10.1016/j.ijpharm.2009.04.002

J. Choi and X. Li, The effect of verapamil on the pharmacokinetics of paclitaxel in rats, European Journal of Pharmaceutical Sciences, vol.24, issue.1
DOI : 10.1016/j.ejps.2004.10.002

F. Rocco, N. Dereudre-bosquet, and P. Clayette, Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006.

D. Desmaële, R. Gref, and P. Couvreur, Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012.
DOI : 10.1016/j.jconrel.2011.07.038

F. Dosio, L. Reddy, A. Ferrero, B. Stella, L. Cattel et al., Novel Nanoassemblies Composed of Squalenoyl???Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation, Bioconjugate Chemistry, vol.21, issue.7
DOI : 10.1021/bc100154g

C. Kruijtzer, J. Beijnen, and J. Schellens, Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview, The Oncologist, vol.7, issue.6, pp.516-530, 2002.
DOI : 10.1634/theoncologist.7-6-516

Y. Lee, S. Kim, and Y. Byun, Oral delivery of new heparin derivatives in rats, Pharmaceutical Research, vol.17, issue.10, pp.1259-1264, 2000.
DOI : 10.1023/A:1026474919869

Y. Lee, J. Nam, H. Shin, and Y. Byun, Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent, Circulation, vol.104, issue.25, pp.3116-3120, 2001.
DOI : 10.1161/hc5001.100627

T. Leonard, D. Coughlan, and A. Cullen, Pharmaceutical compositions of selective factor Xa inhibitors for oral administration, 2011.

D. Leveque and F. Jehl, P-glycoprotein and pharmacokinetics, Anticancer Res, vol.15, pp.331-336, 1995.

J. Meissonnier, N. Sicre, G. Sabate, G. Dubreucq, V. Nancy-portebois et al., Pharmaceutical oral dosage form containing a synthetic oligosaccharide, pp.73408-73410, 2011.

B. Moazed and L. Hiebert, Low Molecular Weight Heparins Cross Rat Gastric Mucosa Mounted in an Ussing Chamber, International Journal of Pharmacology, vol.4, issue.6, pp.431-442, 2008.
DOI : 10.3923/ijp.2008.431.442

S. Peltier, J. Oger, J. Lagarce, F. Couet, W. et al., Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006.
DOI : 10.1007/s11095-006-0022-2

A. Sparreboom, J. Van-asperen, U. Mayer, A. Schinkel, J. Smit et al., Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. USA, pp.2031-2035, 1997.
DOI : 10.1073/pnas.94.5.2031

A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Berknop-schnürch, Development and in vivo bioavailability study of an oral fondaparinux delivery system. Eur, J. Pharm. Sc, p.41, 2010.